Immunovant (IMVT) Notes Payables (2018 - 2019)
Immunovant (IMVT) reported Notes Payables of $300000.0 for Q1 2019, little changed quarter-over-quarter from $300000.0 in Q4 2018.
Immunovant (IMVT) Notes Payables (2018 - 2019) Analysis & Trends
Immunovant has reported Notes Payables for 2 years, with the latest figure at $300000.0 in Q1 2019.
- For the quarter ending Q1 2019, Notes Payables changed N/A year-over-year to $300000.0; the trailing twelve-month figure through Mar 2019 stood at $300000.0 (changed N/A YoY), and the FY2019 full-year result was $300000.0, changed N/A from the prior year.
- Notes Payables for Q1 2019 stood at $300000.0, roughly flat from $300000.0 in the prior quarter.
- The five-year high for Notes Payables was $300000.0 in Q4 2018, with the low at $300000.0 in Q4 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | Immunovant | 5.71 Bn | 5.71 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2019 | 300,000.00 |
| Dec 31, 2018 | 300,000.00 |